Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Crescent Biopharma (CBIO) Invested Capital (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Invested Capital for 11 consecutive years, with $203.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Invested Capital changed N/A to $203.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $203.0 million, a N/A change, with the full-year FY2025 number at $203.0 million, changed N/A from a year prior.
  • Invested Capital was $203.0 million for Q4 2025 at Crescent Biopharma, up from $116.6 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $203.0 million in Q4 2025 to a low of -$30.2 million in Q1 2025.
  • A 5-year average of $68.9 million and a median of $55.7 million in 2022 define the central range for Invested Capital.
  • Biggest YoY gain for Invested Capital was 9058.6% in 2025; the steepest drop was 204.32% in 2025.
  • Crescent Biopharma's Invested Capital stood at $81.6 million in 2021, then plummeted by 47.39% to $42.9 million in 2022, then dropped by 10.52% to $38.4 million in 2023, then crashed by 103.39% to -$1.3 million in 2024, then surged by 15692.32% to $203.0 million in 2025.
  • Per Business Quant, the three most recent readings for CBIO's Invested Capital are $203.0 million (Q4 2025), $116.6 million (Q3 2025), and $139.3 million (Q2 2025).